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Abstract
The 6q25.1 locus was first identified via a genome-wide association study (GWAS) in Chinese women and marked by single
nucleotide polymorphism (SNP) rs2046210, approximately 180 Kb upstream of ESR1. There have been conflicting reports
about the association of this locus with breast cancer in Europeans, and a GWAS in Europeans identified a different SNP,
tagged here by rs12662670. We examined the associations of both SNPs in up to 61,689 cases and 58,822 controls from forty-
four studies collaborating in the Breast Cancer Association Consortium, of which four studies were of Asian and 39 of European
descent. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Case-only analyses were
used to compare SNP effects in Estrogen Receptor positive (ER+) versus negative (ER2) tumours. Models including both SNPs
were fitted to investigate whether the SNP effects were independent. Both SNPs are significantly associated with breast cancer
risk in both ethnic groups. Per-allele ORs are higher in Asian than in European studies [rs2046210: OR (A/G) = 1.36 (95% CI 1.26–
1.48), p = 7.6610214 in Asians and 1.09 (95% CI 1.07–1.11), p = 6.8610218 in Europeans. rs12662670: OR (G/T) = 1.29 (95% CI
1.19–1.41), p = 1.261029 in Asians and 1.12 (95% CI 1.08–1.17), p = 3.861029 in Europeans]. SNP rs2046210 is associated with a
significantly greater risk of ER2 than ER+ tumours in Europeans [OR (ER2) = 1.20 (95% CI 1.15–1.25), p = 1.8610217 versus OR
(ER+) = 1.07 (95% CI 1.04–1.1), p = 1.361027, pheterogeneity = 5.161026]. In these Asian studies, by contrast, there is no clear
evidence of a differential association by tumour receptor status. Each SNP is associated with risk after adjustment for the other
SNP. These results suggest the presence of two variants at 6q25.1 each independently associated with breast cancer risk in
Asians and in Europeans. Of these two, the one tagged by rs2046210 is associated with a greater risk of ER2 tumours.
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Introduction
A genome-wide association study (GWAS) in Chinese women
by Zheng et al. [1] identified a novel breast cancer susceptibility
locus at 6q25.1. The most strongly associated single nucleotide
polymorphism (SNP) was rs2046210, with an estimated Odds ratio
(OR) [per-allele A/G]= 1.29 (95% confidence interval (CI) 1.21–
1.37, p = 10215). SNP rs2046210 did not show a clear association
in GWAS carried out in women of European ancestry, and
replication studies indicated its effect, if any, was weaker in
Europeans [OR (per allele A/G) = 1.04 (95% CI 0.99–1.08),
p = 0.09 in a combined analysis of European studies [2]]. More
recent studies in European women suggested stronger associations
with other SNPs in the region: Turnbull et al. [3] found the most
significantly associated SNP to be rs3757318, which is only weakly
correlated with rs2046210 in Europeans (r2 = 0.09 from in
HapMap2 CEU), while Stacey et al. [2] suggested that SNPs
closer to ESR1may be more strongly associated. It is as yet unclear
whether this difference in breast cancer associated SNPs between
Asians and Europeans indicates the presence of a single or
multiple causative variant(s) at this locus. If there is only one, it is
unlikely to be highly correlated with the best tags identified from
either the Asian or European GWAS and could potentially be a
common variant with a small effect or a rarer one with a larger
effect on breast cancer risk.
In this, by far the largest study to date, we investigate
associations with SNP rs2046210, as well as with SNP
rs12662670 in forty-four case-control studies within the Breast
Cancer Association Consortium (BCAC). These two SNPs have
been genotyped in a total of 120,511 female subjects, of which
110,265 subjects are of European ancestry and 8,559 are Asian.
SNP rs2046210 is the best tag from the original Asian GWAS [1]
and SNP rs12662670 is an easier to genotype surrogate for SNP
rs3757318 - the best tag SNP at the 6q25.1 locus from a European
GWAS [3]. Our aims were to compare the effects of these tags in
well-powered studies of both Asian and European ancestry and to
test if these known SNP associations are shared by the different
ethnic groups. We have been successful in achieving these aims
and our analyses provide additional insights into the nature of this
locus.
Materials and Methods
Ethics Statement
Approval of the studies was obtained from the ethics committees
listed in Table S1. All studies conform to the Declaration of
Helsinki and all study participants gave written informed consent.
Study Populations
Data from forty-five BCAC case-control studies from Australia,
Europe, North America, and South-East Asia were available for
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inclusion in this analysis (see Table S1 for a description of the
individual studies). To be eligible for BCAC, studies needed to
include at least 500 cases of invasive breast cancer and 500
controls, with DNA samples available for genotyping. The controls
needed to be broadly from the same population as the cases
(http://www.srl.cam.ac.uk/consortia/bcac/about/about.html).
Some studies selected cases preferentially on the basis of age and/
or family history.
All studies provided information on disease status (58,822
controls/62,061 invasive cases/2,769 in-situ cases/1,435 cases of
unknown invasiveness), age at diagnosis or interview and ethnicity
(Asian/European/other). Forty studies also provided information
on estrogen receptor (ER) status for a total of 40,508 cases (9,878
Estrogen receptor negative (ER2)/30,630 Estrogen Receptor
positive (ER+)).
Laboratory Methods
In most studies SNPs were assayed by TaqmanTM (Applied
Biosystems, Foster City, USA). Primers, probes and master mix
were ordered in a single batch and alliquots shipped to each study.
Reactions were performed according to manufacturer’s instruc-
tions, using the following thermal cycling profile 95uC for 10 mins
followed by: [92uC for 15 secs, 60uC for 1 min] for 40–60 cycles.
SNP rs12662670 was chosen as the most easily assayable
surrogate for the best European GWAS hit, rs3757318, for which
no working TaqmanTM assay could be designed. These two SNPs
are correlated at r2 = 0.89 in the European samples used in
Turnbull et al. [3] although the correlations in populations of
Asian ancestry are somewhat weaker (r2 = 0.72 and r2 = 0.66 in
HapMap2 JPT and CHB samples, respectively).
The primer and probe sequences used were:
For SNP rs2046210
Forward primerTGCCTCAACTGTCTTGTGAATCTTT
Reverse primerCTACTGTAGAATCATTTTCCTCACACA-
TACA
G allele probeVIC ACAGTCACATACGCATCTA
A allele probe FAM CAGTCACATACACATCTA
For SNP rs12662670
Forward primerCTAACGAAGGCAGAGCAAAAAGAAA
Reverse primerCACACATGCATGACACGTAAATCTT
T allele probeVIC ATTAAATTCTTGTAAGTTTCC
G allele probe FAM AATTCTTGTCAGTTTCC
Four studies (ACP, GESBC, kConFab/AOCS and MARIE)
used the Sequenom iPLEX MassARRAYTM system (Sequenom,
San Diego, CA, USA) with oligonucleotide design performed
using MassARRAY Assay Design software (version 3.1).
SNPs were genotyped in three different BCAC genotyping
phases along with other SNPs of interest to the consortium (see
Tables S2a and S2b for information on the respective phases for
SNPs rs2046210 and rs12662670). All studies followed standard
quality control guidelines (for details see http://www.srl.cam.ac.
uk/consortia/bcac/about/about.html). Data were excluded for
any sample that failed genotyping for .20% of the SNPs typed in
a given phase of genotyping. All study data were excluded for any
SNP with overall call rate ,95% or duplicate concordance ,94%
(based on at least 2% of samples in each study being genotyped in
duplicate) or departure of genotype distribution from Hardy-
Table 1. Association of rs2046210 and rs12662670 with breast cancer.
Ethnicity
Number
of cases/controls Odds ratio (95% confidence interval) P-valuea
per alleleb Heterozygotec Homozygotec
rs2046210
Analyses adjusted for study
Overall 54,647/49,559 1.10 (1.08–1.13) 1.11 (1.08–1.14) 1.22 (1.17–1.27) 3.30610225
Europeans 49,634/46,679 1.09 (1.07–1.11) 1.09 (1.06–1.12) 1.18 (1.13–1.23) 6.76610218
Asians 2983/2332 1.36 (1.26–1.48) 1.39 (1.23–1.56) 1.83 (1.54–2.18) 7.60610214
Analyses adjusted for study and rs12662570
Overall 40,384/33,750 1.08 (1.05–1.11) 1.08 (1.05–1.12) 1.16 (1.10–1.23) 3.0661029
Europeans 36,396/31,105 1.08 (1.05–1.11) 1.08 (1.04–1.12) 1.16 (1.09–1.22) 1.7861028
Asians 3416/2420 1.17 (1.02–1.36) 1.18 (0.99–1.41) 1.37 (1.02–1.85) 0.028
rs12662670
Analyses adjusted for study
Overall 42,654/40,166 1.15 (1.12–1.19) 1.15 (1.10–1.19) 1.40 (1.23–1.58) 2.52610216
Europeans 38,723/37,400 1.12 (1.08–1.17) 1.13 (1.09–1.18) 1.12 (0.94–1.34) 3.8361029
Asians 3273/2451 1.29 (1.19–1.41) 1.24 (1.10–1.39) 1.77 (1.46–2.14) 1.1861029
Analyses adjusted for study and rs2046210
Overall 40,384/33,750 1.10 (1.06–1.15) 1.10 (1.05–1.15) 1.25 (1.08–1.45) 5.8661026
Europeans 36,396/31,105 1.07 (1.02–1.12) 1.09 (1.03–1.14) 1.01 (0.83–1.23) 2.9161023
Asians 3416/2420 1.21 (1.04–1.40) 1.16 (0.97–1.38) 1.55 (1.12–2.13) 0.012
Results are presented overall and separately for Europeans and Asians. Pooled analyses adjusted for study only as well as adjusted for rs12662670 or rs2046210,
respectively, in addition to study were performed.
aP-value derived from the log-additive model.
bOdds ratio per minor allele (A allele for rs2046210, G allele for rs12662670).
cOdds ratio relative to the major allele homozygous (GT) genotype.
doi:10.1371/journal.pone.0042380.t001
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Weinberg equilibrium in controls (p,0.005). In addition, all
genotyping centres assayed an identical plate of 80 control DNA
samples (referred to as the Coriell plate; which also included 14
internal duplicates) and had to achieve call rates and duplicate
concordance .98% in order for their data to be included. Data
for both SNPs from one study (NBCS) were excluded from further
analyses after quality control rules were applied. Quality control
data for the individual studies are shown in Tables S2a and S2b.
Thus, for SNP rs2046210 forty out of forty-one assayed studies
(56,607 cases/49,559 controls), and for SNP rs12662670 thirty-
three out of thirty-four assayed studies (47,251 cases/40,161
controls) were included in the statistical analysis.
Statistical Analyses
ORs were estimated using logistic regression. In order to
provide reliable estimates of effect sizes, study-specific effect
estimates of ORs were derived only for those studies that provided
at least 100 cases and controls for the respective (sub-) group of
interest.
The primary analysis estimated ORs for the main effect of the
SNP, adjusted for the studies that provided data for the respective
analysis (i.e. S-1 indicator variables were entered the logistic
regression model, where S was number of studies that provided
data for the respective analysis). ORs adjusted for both study and
age were essentially identical and we did not therefore present the
age-adjusted analyses. Per allele ORs were estimated under the
assumption of a log-additive mode of inheritance, i.e. the SNP was
coded according to the number of minor alleles 0, 1 or 2.
Additionally, ORs by genotype were calculated, i.e. two indicator
variables indicating the presence of the heterozygous genotype and
the genotype homozygous for the minor allele, respectively, were
entered the model. The primary p-values were derived by means
of a Wald-Test assuming a log-additive mode of inheritance (one
degree of freedom). Following Laird and Mosteller, heterogeneity
of per allele ORs between studies was assessed by the p-value
derived from the Q statistic [4] and using I2. Tests were two-sided.
Genetic main effects by ER status were estimated using case-
control logistic regression and restricting the case sample to ER+
or ER2 cases, respectively. To test for significant differences
between main effects of rs2046210 or rs12662670 in ER+ versus
ER2 cases, logistic regression analyses were conducted in cases
only. In these case-only analyses, the binary ER status was the
outcome/dependent variable and the respective SNP and the
indicator variables representing the studies were the independent
variables.
Variation in OR by age was evaluated by testing for an
interaction between age-group (,40, 40 to 49, 50 to 59, $60) and
SNP, separately for each subgroup defined by ethnicity and ER
Figure 1. Association of rs2046210 with breast cancer in Europeans versus Asians.
doi:10.1371/journal.pone.0042380.g001
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Table 2. Association of haplotypes composed of rs2046210 and rs12662670 with breast cancer.
Ethnicity
Number of
cases/controls rs2046210 rs12662670
Haplotype
frequency
Odds ratio (95%
confidence
interval)a P-valueb
Overall 40,384/33,750 Ac T 0.26 1.08 (1.05–1.11) 1.5561029
G Gc 0.01 1.10 (0.95–1.27) 0.189
Ac Gc 0.09 1.23 (1.18–1.28) 2.2061024
Gd Td 0.64d – –
Europeanse 36,396/31,105 Ac T 0.27 1.08 (1.05–1.11) 1.5961028
G Gc 0.01 1.02 (0.86–1.21) 0.832
Ac Gc 0.07 1.16 (1.11–1.21) 4.35610211
Gd Td 0.65d – –
Asianse 3416/2420 Ac T 0.09 1.23 (1.05–1.45) 1.1561022
G Gc 0.04 1.23 (0.94–1.61) 0.134
Ac Gc 0.27 1.42 (1.30–1.56) 4.44610214
Gd Td 0.60d – –
Results are presented overall and separately for Europeans and Asians. Pooled analyses adjusted for study were performed.
aOdds ratio per haplotype compared to the reference haplotype (i.e., the most frequent haplotype).
bP-value derived from the log-additive model.
cMinor allele.
dReference haplotype.
doi:10.1371/journal.pone.0042380.t002
Figure 2. Association of rs12662670 with breast cancer in Europeans versus Asians.
doi:10.1371/journal.pone.0042380.g002
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status. Thus, the multiplicative SNP by age-group interaction term
entered the model in addition to the main effect terms for SNP,
age-group and study.
To investigate whether the association with breast cancer risk
could be explained by one SNP or whether both SNPs had
independent effects on disease risk, we fitted logistic regression
models which included both SNPs, in addition to indicator
variables for the studies, as independent variables in the model.
Analyses were carried out separately for Europeans and Asians
and for ER2 versus ER+ cases and controls. Additionally,
haplotype analyses were performed using logistic regression
models that included the estimated two-marker haplotypes (coded
according to a log-additive model) except for the reference
haplotype (i.e., the most frequent haplotype) and the indicator
variables for study. Haplotypes were estimated using the
expectation-maximization algorithm.
All analyses, were performed using R version 2.11.0 [5] and the
R packages meta, rmeta and haplo.stats.
Results
Key characteristics for each participating study are shown in
Table S1. In addition to the originally discovered SNP
rs2046210, SNP s12662670 was genotyped as a surrogate for
the best tag from Turnbull et al. (rs3757318) [3], for which no
working TaqmanTM assay could be designed. The genotype
distributions by ethnicity and study for SNPs rs2046210 and
rs12662670 in cases and controls are given in Tables S3a and
Table 3. Association of rs2046210 and rs12662670 with risk of ER2*/ER+** breast cancer.
Ethnicity
Estrogen
receptor status
Number of
cases/controls
Odds ratio (95% confidence
interval)a P-valueb P-heterogeneityc
rs2046210
Analyses adjusted for study
Overall ER2* 7126/35,833 1.23 (1.18–1.28) 6.90610225
ER+** 5914/32,977 1.09 (1.06–1.12) 1.66610211 5.9361027
Europeans ER2* 807/2334 1.20 (1.15–1.25) 1.77610217
ER+** 24,596/42,664 1.07 (1.04–1.10) 1.2661027 5.1061026
Asians ER2* 22,336/39,856 1.45 (1.29–1.64) 1.7061029
ER+** 1307/2334 1.35 (1.22–1.49) 1.0961028 0.513
Analyses adjusted for study and rs12662670
Overall ER2* 5526/25,627 1.19 (1.13–1.26) 1.26610210
ER+** 19,502/32,010 1.07 (1.03–1.10) 7.2661025 1.0161023
Europeans ER2* 4497/23,090 1.20 (1.13–1.26) 4.54610210
ER+** 17,653/29,365 1.07 (1.03–1.10) 2.1661024 4.6361024
Asians ER2* 975/2420 1.16 (0.94–1.44) 0.169
ER+** 1649/2420 1.13 (0.94–1.35) 0.194 0.777
rs12662670
Analyses adjusted for study
Overall ER2* 5422/28,201 1.23 (1.15–1.32) 6.1661029
ER+** 4563/26,198 1.14 (1.09–1.19) 3.0561028 0.074
Europeans ER2* 808/1890 1.17 (1.08–1.27) 1.9061024
ER+** 20,095/34,460 1.09 (1.04–1.15) 6.0861024 0.070
Asians ER2* 18,519/32,349 1.37 (1.20–1.56) 3.3061026
ER+** 1394/1890 1.35 (1.21–1.51) 1.5861027 0.691
Analyses adjusted for study and rs2046210
Overall ER2* 5526/25,627 1.10 (1.01–1.20) 0.028
ER+** 19,502/32,010 1.09 (1.03–1.15) 2.1461023 0.87
Europeans ER2* 4497/23,090 1.03 (0.94–1.14) 0.516
ER+** 17,653/29,365 1.05 (0.99–1.11) 0.110 0.92
Asians ER2* 975/2420 1.33 (1.07–1.65) 0.011
ER+** 1649/2420 1.26 (1.04–1.52) 0.017 0.30
Results are presented overall as well as separately for Europeans and Asians. Pooled analyses adjusted for the studies were performed. A log-additive genetic model was
assumed.
*Estrogen receptor negative.
**Estrogen receptor positive.
aOdds ratio per minor allele (A allele for rs2046210, G allele for rs12662670) derived from case-control logistic regression restricted to ER+ or ER2 cases, respectively, and
the whole control sample.
bP-value derived from the log-additive model derived from case-control logistic regression restricted to ER+ or ER2 cases, respectively, and the whole control sample.
cP-value for heterogeneity between estimates of genetic main effects derived from case-only analysis.
doi:10.1371/journal.pone.0042380.t003
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S3b. The associations of each SNP are presented in Table 1 and
as Forest plots in Figure 1 and 2, separately for Europeans and
Asians. Both SNPs are significantly associated with breast cancer
risk in both ethnic groups. However, the per-allele OR associated
with the minor A allele of SNP rs2046210 is higher in Asian
populations [OR (A/G)= 1.36 (95% CI 1.26–1.48),
p = 7.6610214] than in Europeans [OR (A/G) = 1.09 (95% CI
1.07–1.11), p = 6.8610218] and this difference is statistically
significant [pheterogeneity = 1.4610
27]. SNP rs12662670 shows a
similar pattern, with a higher OR associated with the minor G
allele in Asian studies [OR (G/T) = 1.29 (95% CI 1.19–1.41),
p = 1.261029] than in Europeans [OR (G/T) = 1.12 (95% CI
1.08–1.17), p = 3.861029] and again this difference is statistically
significant [pheterogeneity = 0.002]. In each case there is no evidence
for departure from a log-additive model (a co-dominant mode of
inheritance).
Logistic regression models, which include both SNPs, indicate
that the two SNPs are independently associated in both Europeans
(p = 1.861028 for rs2046210, p = 2.961023 for rs12662670;
Table 1) and Asians (p= 0.028 for rs2046210, p = 0.012 for
rs12662670). In each ethnicity the estimated ORs for each SNP,
after adjustment for the other SNP, are of similar magnitudes: For
rs2046210 in Europeans OR (A/G)= 1.08 (95% CI 1.05–1.11)
and for rs12662670 in Europeans OR (G/T) = 1.07 (95% CI
1.02–1.12). For rs2046210 in Asians OR (A/G)= 1.17 (95% CI
1.02–1.36) and for rs12662670 in Asians OR (G/T) = 1.21 (95%
CI 1.04–1.40). Similar effect estimates are also obtained for
haplotypes carrying one minor allele though estimates do not
reach statistical significance for the very rare haplotype carrying
the major (G) allele of rs2046210 along with the minor (G) allele of
rs12662670 (Table 2). Of note, from the four observed
haplotypes, effects are strongest and highly statistically significant
for the haplotype carrying both minor alleles: In Europeans OR
(AG)= 1.16 (95% CI 1.11–1.21). In Asians OR (AG) = 1.42 (95%
CI 1.30–1.56).
The OR estimates for in-situ cancer are similar to those for
invasive cancer for both SNPs in Europeans, although, due to
small numbers, the effect of rs12662670 on in-situ tumours does
not reach statistical significance (Table S4). For each Asian study,
the number of in-situ cases is less than 100 and so effect estimates
are inaccurate but do not differ from those for invasive cancer
(data not shown).
Figure 3. Association of rs2046210 with breast cancer in European ER2*versus ER+*cases and controls. *Estrogen receptor negative;
**Estrogen receptor positive.
doi:10.1371/journal.pone.0042380.g003
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The associations of these two SNPs with tumour sub-types
defined by ER status (ER+ and ER2) were also investigated and
are presented in Table 3 and Figures 3, 4, 5, and 6. In
Europeans, SNP rs2046210 is associated with a greater OR for
ER2 than ER+ tumours: OR (ER2) = 1.20 (95% CI 1.15–1.25),
p = 1.8610217 vs. OR (ER+) = 1.07 (95% CI 1.04–1.1),
p = 1.361027, pheterogeneity = 5.1610
26. This difference remains
significant after adjustment for rs12662670. A similar, although
non-significant, difference is observed in European women for
SNP rs12662670 (Table 3). In the Asian studies, however, there is
no clear evidence of a differential association by tumour receptor
status for either SNP (Table 3).
We further investigated whether the magnitudes of these SNP
associations on tumour sub-types differed by age at diagnosis/
interview (see Table S5). In Asian studies the data are too sparse
to give meaningful results. In the combined ethnicities and the
European studies alone, the magnitudes of the observed associa-
tions are greater in younger women.
Fourteen of the European studies had been designed to over-
sample cases with a family history of breast cancer (see Table S1),
which could have led to an overestimation of the ORs relative to
those expected in a population-based case-control study. However,
exclusion of these studies does not materially affect the estimated
ORs for either SNP (see Table S6).
Discussion
In this large collaborative study of up to 61,689 cases and
58,822 controls, we demonstrate a highly statistically significant
association between the A allele of rs2046210 and increased breast
cancer risk in women of both Asian and European ancestry, thus
extending the association previously observed in Asian popula-
tions. Consistent with previous reports [1–3], the effect sizes are
significantly greater in Asians than in Europeans. Our study also
reveals that the G allele of SNP rs12662670 is significantly
associated with increased breast cancer risk in both ethnicities.
SNP rs12662670 is used here as surrogate for SNP rs3757318 - the
most strongly associated SNP at this locus in the European GWAS
described by Turnbull et al. [3]. In addition, and also in contrast
to Stacey et al. [2], we find that the OR for rs12662670 is greater
in Asians than in Europeans (Table 1, Figure 1 and 2). In
contrast to previous reports, our study indicates that both SNPs
(rs2046210 and rs12662670) may be independently associated
with breast cancer risk – in models including both SNPs, both
Figure 4. Association of rs2046210 with breast cancer in Asian ER2*versus ER+**cases and controls. *Estrogen receptor negative;
**Estrogen receptor positive.
doi:10.1371/journal.pone.0042380.g004
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maintain significant ORs after adjustment for the other. Haplo-
type analyses result in effect estimates for the AT and GG
haplotypes, which carry only one minor allele, very similar to those
of the single SNP analyses for the respective minor alleles.
Furthermore, haplotype analyses show a clearly stronger effect of
the AG haplotype, carrying both minor alleles, compared to the
effects of the AT and GG haplotypes, further supporting the
hypothesis that there may be two different causative variants, one
on each haplotype carrying only one minor allele and both on the
haplotype carrying both minor alleles (i.e., the stronger effect of
the AG haplotype compared to the AT and GG haplotypes may
be explained by the joint effect of the two minor alleles on the AG
haplotype). However, the alternative conclusion that a single
causative variant may exist that is intermediate between the two
SNPs phylogenetically, i.e. on the AG haplotype and on some of
the AT haplotypes, cannot yet be completely excluded, since this
could also be an explanation for the stronger effect of the AG
haplotype compared to the AT and GG haplotypes.
We also find evidence that SNP rs2046210 is more strongly
associated with ER2 than ER+ disease in both European and
Asian women. In the present study this differential association with
receptor status is statistically significant in European studies (and
remains after adjustment for rs12662670) but is not quite
significant in Asians which may be due to a lack of power attributable
to the comparatively small number of Asian individuals involved in
our study (Table 3). However this same SNP had previously been
reported to be more strongly associated with ER2 tumours in the
original Chinese cases [1] as well as in a recent replication study in
Chinese women [6]. In line with these reports, a meta-analysis
(14,231 cases, 10,244 controls) on this SNP-disease association by ER
status in Asians, incorporating published results as well as those
presented here, reveals a significant difference in OR associated with
ER2 versus ER+ tumour risk [OR (A/G - ER2 ) = 1.37 (95% CI
1.30–1.44), p=3.7610233 vs. OR (A/G- ER+) = 1.27 (95% CI
1.22–1.34), p=2.2610224; pheterogeneity = 0.04]. A stronger associ-
ation of SNP rs2046210 with ER2 tumours is also consistent with the
report from the Consortium of Modifiers of BRCA1/2 (CIMBA) [7]
that the same allele is associated with an increased Hazard Ratio of
breast cancer in BRCA1 mutation carriers (who predominantly
develop ER2 tumours). The CIMBA study also observed that this
allele conferred increased Hazard Ratios among younger mutation
carriers while we observed similar trends for greater SNP ORs at
younger age groups (Table S5). By contrast, the CIMBA consortium
reported that SNP rs9397435 (the tag they used for rs12662670;
r2 =0.61, r2= 0.50 and r2=0.85 in HapMap2 CEU, JPT and CHB
samples, respectively) shows evidence of modification of risk in both
Figure 5. Association of rs12662670 with breast cancer in European ER2*versus ER+**cases and controls. *Estrogen receptor negative;
**Estrogen receptor positive.
doi:10.1371/journal.pone.0042380.g005
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BRCA1 and BRCA2 mutation carriers (who mainly develop ER2
and ER+ tumours respectively) [7] whilst similarly, we find that SNP
rs12662670 is associated with increased risks of both ER2 and ER+
tumours.
Previous fine-scale mapping publications on this locus [2,8]
have sought a single variant to explain the associations seen with
all SNPs in the region: Stacey et al. [2] proposed SNP rs9397435
as a possible single causative variant since it was more strongly
associated than rs2046210 in women of European, African and
Asian ancestry. We are not able to comment on this variant, as it
has not been genotyped in BCAC. However, our findings suggest
there could be two independent associations at this locus: one,
better tagged by SNP rs2046210, predisposing to ER2 tumours
and the second, better tagged by rs12662670, conferring similar
risks of both tumour types. Although physically close, SNPs
rs2046210 and rs12662670 are not highly correlated with each
other, particularly in Europeans (in BCAC r2 = 0.12 in Europeans
and r2 = 0.56 in Asians) and all four possible combinations
(haplotypes) of these two SNPs clearly exist.
Examination of linkage disequilibrium plots of the regions
surrounding these two SNPs in Europeans (Figure 7) reveals little,
if any, physical overlap between SNPs highly correlated (r2.0.9)
with rs2046210 and those with rs12662670. If there were a single
causal variant, directly responsible for the associations seen with
both SNPs, it would need to be correlated with both SNPs. Such a
variant has not been yet identified (e.g. by the 1000 Genomes
Project). It would presumably be relatively rare. An alternative,
and we think, more plausible, explanation for the pattern of
associations may be the existence of two independent causative
variants, one correlated with rs2046210 and another correlated
with rs12662670. If this is the case, the former variant may be
more strongly associated with ER2 breast cancer than the latter.
The reason why both SNPs confer higher relative risks in Asians
than in Europeans is unclear. Within the BCAC studies, ER2
tumours are relatively more prevalent among Asian (36%)
compared to European cases (23%), but this is not sufficient to
explain the higher ORs in Asians, since the effects persist after
stratification by ER status. It remains possible that the higher
relative risks are due to differential patterns of linkage disequilib-
rium if the, as yet, unidentified causal variants are not strongly
correlated with the SNPs identified to date. These questions may
be resolved by comprehensive re-sequencing of this locus and fine
scale mapping to identify the causal variant (or variants)
responsible for the observed breast cancer risks. One aim of the
Figure 6. Association of rs12662670 with breast cancer in Asian ER2*versus ER+*cases and controls. *Estrogen receptor negative;
**Estrogen receptor positive.
doi:10.1371/journal.pone.0042380.g006
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iCOGS Project [9], which is currently underway, is to address
these questions. However it is possible that these observed
differences between Asians and Europeans may reflect interactions
with lifestyle risk factors or other unlinked genetic loci. Another
possible explanation is that the estimated SNP effects in Asians are
inflated given the phenomenon known as the ‘‘winner’s curse’’, i.e.
the suboptimal power of the pool of Asian studies (due to the small
number of Asian individuals) together with the commonly used
requirement for a published association to pass a certain pre-
defined p-value threshold may have resulted in biased SNP effect
estimates [10,11].
Although there are eleven genes within 1 Mb of this locus,
attention has focused on the ESR1 gene, whose transcription start
site is located approximately 180 Kb downstream of SNP
rs2046210. ESR1 encodes ERa and has long been implicated in
breast carcinogenesis. However, it is possible that the proximity of
this SNP to ESR1 may be providing a false lead – both SNPs
(rs2046210 and rs12662670) lie in the flanking region of C6orf97
and there are numerous other genes in close physical proximity
(see Figure 7). It is notable however, that SNPs mapping to this
region have also been identified in GWAS for bone mineral
density – another phenotype in which estradiol metabolism is
clearly implicated [12,13]. Furthermore, a recent paper [14]
demonstrates that a number of genes, including ESR1 and C6orf97
are co-regulated at this locus although the functions of most of
these co-regulated genes have not yet been elucidated. The SNP
associations, presented here, may provide a basis to explore the
biological role of this locus in estrogen signalling and cancer
development in more detail.
Taken together our findings suggest the possibility of the
presence of two different causative variants at the 6q25.1 locus and
indicate that fine-scale mapping efforts aimed at finding a single
variant accounting for associations with both marker SNPs, may
not be successful.
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